OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/NTRK1
Lung Cancer — Non-Small Cell (NSCLC)NTRK1 Clinical Trials
NTRK1 fusions are rare drivers in NSCLC (<1%) but respond to tumor-agnostic NTRK inhibitors larotrectinib and entrectinib, both FDA-approved regardless of cancer type. Resistance emerges via acquired kinase domain mutations. Trials investigate next-generation NTRK inhibitors designed to overcome on-target resistance.
Top recruiting NTRK1 Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
ImmunityBio, Inc.
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
BioNTech SE
More NTRK1 Lung Cancer — Non-Small Cell (NSCLC) trials
6 international trials (no US sites)
FDA-approved therapies for NTRK1 Lung Cancer — Non-Small Cell (NSCLC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.